Five Prime Therapeutics (NASDAQ:FPRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

According to Zacks, “Five Prime Therapeutics, Inc. is a biotechnology company. The company focuses on the discovery and development of protein therapeutics that blocks cancer and inflammatory disease processes. It operates primarily in the United States and Canada. Five Prime Therapeutics, Inc. is based in San Francisco, California. “

FPRX has been the subject of several other reports. Royal Bank of Canada increased their price objective on shares of Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, November 6th. BidaskClub cut shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. BMO Capital Markets increased their price objective on shares of Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 7th. Finally, ValuEngine cut shares of Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, November 7th. Three research analysts have rated the stock with a sell rating and six have issued a buy rating to the company. Five Prime Therapeutics has an average rating of “Hold” and a consensus price target of $64.00.

Five Prime Therapeutics (FPRX) traded down $0.08 on Wednesday, hitting $19.09. 461,422 shares of the stock traded hands, compared to its average volume of 558,906. Five Prime Therapeutics has a 52 week low of $17.05 and a 52 week high of $49.30. The firm has a market capitalization of $637.02, a PE ratio of -3.77 and a beta of 3.56.

A number of large investors have recently bought and sold shares of FPRX. Northern Trust Corp grew its holdings in Five Prime Therapeutics by 1.1% in the second quarter. Northern Trust Corp now owns 335,488 shares of the biotechnology company’s stock worth $10,102,000 after purchasing an additional 3,770 shares during the period. Ark Investment Management LLC grew its holdings in shares of Five Prime Therapeutics by 299.2% during the second quarter. Ark Investment Management LLC now owns 14,174 shares of the biotechnology company’s stock valued at $427,000 after buying an additional 10,623 shares during the last quarter. Parametric Portfolio Associates LLC grew its holdings in shares of Five Prime Therapeutics by 140.9% during the second quarter. Parametric Portfolio Associates LLC now owns 23,894 shares of the biotechnology company’s stock valued at $719,000 after buying an additional 13,977 shares during the last quarter. Virtu KCG Holdings LLC acquired a new position in shares of Five Prime Therapeutics during the second quarter valued at about $331,000. Finally, Voya Investment Management LLC grew its holdings in shares of Five Prime Therapeutics by 9.5% during the second quarter. Voya Investment Management LLC now owns 12,594 shares of the biotechnology company’s stock valued at $379,000 after buying an additional 1,097 shares during the last quarter. Institutional investors and hedge funds own 72.14% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Five Prime Therapeutics (FPRX) Downgraded by Zacks Investment Research” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.thecerbatgem.com/2018/02/14/five-prime-therapeutics-fprx-downgraded-by-zacks-investment-research.html.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.